Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - Changlian Co., Ltd. will invest 30 million yuan, accounting for 60% of the registered capital of the new company [1] - The registered capital of the new company is set at 50 million yuan, with a profit distribution ratio of no less than 60% of the annual net profit [1] - The investment is expected to be completed by January 30, 2026 [1]

Core Points - On November 12, Century Huatong announced a share repurchase plan of 500 million to 1 billion yuan for capital reduction [1][2] - A total of 18 A-share listed companies disclosed share reduction plans, indicating a trend of shareholder divestment [1][2] Summary of Share Repurchase - Century Huatong plans to repurchase shares worth between 500 million and 1 billion yuan to reduce registered capital [2] Summary of Share Reductions - Tai Xiang Co. plans to reduce no more than 1% of its shares by shareholder Zhongyuan Investment [2] - Jiang Bolong's second-largest shareholder has completed a reduction of 4.1915 million shares [2] - Senior management of Zhejiang Zhongcheng plans to reduce their holdings [2] - Controlling shareholder of Hexing Packaging intends to reduce no more than 1.91% of shares [2] - Shareholder Wang Ge of Dongfang Zhongke plans to reduce no more than 0.51% of shares [2] - Executive Yu Qingchi of Kuai Publishing plans to reduce no more than 0.02% of shares [2] - Directors and executives of Changlian Co. plan to collectively reduce no more than 0.77% of shares [2] - China Unicom's structural adjustment fund reduced 40.7003 million shares from November 10 to November 12 [2] - Shareholder Chen Bei of Ruimaite plans to reduce no more than 1.76% of shares [2] - Shareholder Zhang Hong of Aipeng Medical plans to reduce no more than 2% of shares [2] - Director Wo Jinye of Jujiao Co. plans to reduce no more than 0.01% of shares [2] - Directors and executives of Zhonglan Environmental Protection plan to reduce their holdings [2] - Shareholders Ning Kangqi and Beikangqi of Hendi Pharmaceutical plan to collectively reduce no more than 2.33% of shares [2] - Wuxi High-tech Zone New Momentum Industry Development Fund reduced 549,200 shares of Xiangnan Chip [2] - Controlling shareholder of Tianji Co. sold 8.4 million shares during a period of significant stock trading volatility [2] - The second-largest shareholder of Fangzheng Electric reduced a total of 1.6324 million shares on November 10 and 12 [2] - Controlling shareholder of Haodangjia plans to reduce no more than 2.7% of shares [2] - Controlling shareholder of Zhibang Home reduced 905,000 convertible bonds [2]

Summary of Key Points Core Viewpoint - The article discusses various companies and their shareholders' intentions to buy or sell shares, indicating a trend of both increasing and decreasing shareholdings among different firms in the market [1]. Company Actions - 康缘药业's actual controller's concerted action party increased holdings by 80,000 shares [1]. - 好当家's controlling shareholder plans to reduce holdings by no more than 2.7% [1]. - 亨迪药业's shareholders, including 宁康企管, 倍康企管, and 雷小艳, intend to collectively reduce holdings by no more than 2.33% [1]. - 合兴包装's controlling shareholder 新疆兴汇聚 plans to reduce holdings by no more than 1.91% [1]. - 瑞迈特's shareholder 陈蓓 intends to reduce holdings by no more than 1.76% [1]. - 泰祥股份's 众远投资 plans to reduce holdings by no more than 1% [1]. - 香农芯创's 无锡高新区新动能产业发展基金 reduced holdings by 549,200 shares [1]. - 中国联通's structural adjustment fund will reduce holdings by 40,700,300 shares from November 10 to November 12 [1]. - 方正电机's shareholder 张敏 reduced holdings by 1,632,400 shares [1]. - 畅联股份's directors 徐峰 and 陈文晔 plan to reduce holdings by 0.57% and 0.20%, respectively [1]. - 中兰环保's shareholders 王广庆, 曹丽, and 李泉 plan to reduce holdings by 0.0375%, 0.2798%, and 0.0275%, respectively [1]. - 聚胶股份's director 沃金业 plans to reduce holdings by 0.01% [1]. - 浙江众成's executives 黄旭生 and 潘德祥 plan to reduce holdings by 0.0140% [1]. - 东方中科's shareholder 王戈 plans to reduce holdings by 0.51% [1]. - 海南瑞泽's vice president 于清池 plans to reduce holdings by no more than 0.02% [1].

畅联股份(603648.SH)发布公告，自本公告发布之日起十五个交易日后的三个月内，即2025年12月4日至 2026年3月3日，公司董事、总经理徐峰先生计划通过上海证券交易所交易系统集中竞价交易方式进行减 持，拟减持不超过206.52万股公司股份,占公司总股本的0.57%;公司董事、副总经理陈文晔女士计划通过 上海证券交易所交易系统集中竞价交易方式进行减持，拟减持不超过73.64万股公司股份,占公司总股本 的0.20%。 ...

畅联股份（603648）(603648.SH)发布公告，自本公告发布之日起十五个交易日后的三个月内，即2025 年12月4日至2026年3月3日，公司董事、总经理徐峰先生计划通过上海证券交易所交易系统集中竞价交 易方式进行减持，拟减持不超过206.52万股公司股份,占公司总股本的0.57%;公司董事、副总经理陈文晔 女士计划通过上海证券交易所交易系统集中竞价交易方式进行减持，拟减持不超过73.64万股公司股份, 占公司总股本的0.20%。 ...

1 证券代码：603648 证券简称：畅联股份 公告编号：2025-028 上海畅联国际物流股份有限公司 部分董事、高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董事、高级管理人员持股的基本情况 截至本减持计划披露日，上海畅联国际物流股份有限公司（以下简称 "公司"）董事、总经理徐峰先生持有公司股份 4,720,362 股，约占公 司总股本的 1.30%；公司董事、副总经理陈文晔女士持有公司股份 1,683,230 股，约占公司总股本的 0.46%。上述股份全部为公司首次公 开发行股票前已持有的股份，该部分股份已于 2018 年 9 月 13 日解除 限售并上市流通。 减持计划的主要内容 自本公告发布之日起十五个交易日后的三个月内，即 2025 年 12 月 4 日至 2026 年 3 月 3 日，公司董事、总经理徐峰先生计划通过上海证券 交易所交易系统集中竞价交易方式进行减持，拟减持不超过 2,065,158 股公司股份,占公司总股本的 0.57%；公司董事、副总经理 ...

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish a joint venture named Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - The investment agreement was signed on November 12, 2025, with Changlian Co. contributing 30 million yuan, which represents 60% of the new company's registered capital [1] - Shanghai Waigaoqiao Biopharmaceutical will contribute 20 million yuan, accounting for 40% of the registered capital [1] - Both parties will collectively hold 100% of the new company's registered capital [1]

证券代码：603648 证券简称：畅联股份 公告编号：2025-027 上海畅联国际物流股份有限公司 二、本次对外投资进展情况 2025 年 11 月，公司与生物医药公司正式签署《出资协议》，主要内容如下： （一）出资协议签署主体 关于对外投资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 投资标的名称 | 上海畅联百福医药有限公司 | | --- | --- | | 投资金额（万元） | 3,000 万元 | | 投资进展情况 | 正式签署协议 | | 特别风险提示（如有） | 无 | 一、对外投资基本情况 经上海畅联国际物流股份有限公司（以下简称"公司"或"畅联股份"） 第四届董事会第十二次会议、第四届监事会第十次会议、第四届董事会审计委 员会第十三次会议、第四届董事会独立董事专门会议第四次会议审议通过，同 意公司与上海外高桥生物医药产业发展有限公司（以下简称"生物医药公司"） 合资新设上海畅联百福医药有限公司（以下简称"畅联百福"或"新公司"）， 具 体 内 容 详 见 公 司 ...

每经AI快讯，11月12日，畅联股份（603648）公告，公司董事、总经理徐峰拟通过集中竞价交易方式 减持不超过206.52万股公司股份，占公司总股本的0.57%；公司董事、副总经理陈文晔拟减持不超过 73.64万股公司股份，占公司总股本的0.20%。上述减持计划将在2025年12月4日至2026年3月3日期间实 施，减持价格视市场价格确定，减持原因为自身资金需要。本次减持股份来源均为公司首次公开发行股 票前已持有的且已解除限售的股份。 ...